Figure 5
Figure 5. AURKA207-215–specific TCR-transduced CD8+ T cells kill freshly isolated leukemia cells in vitro. Freshly isolated HLA-A*0201+ (n = 3) or HLA-A*0201− (n = 3) acute or chronic myeloid leukemia cells overexpressing AURKA mRNA were used as targets in 51Cr-release assays with AURKA207-215–specific TCR-transduced CD8+ T cells at the indicated effector:target (E/T) ratios. AML, acute myeloid leukemia; BC, blast crisis; CML, chronic myeloid leukemia. M1, M2, and M4 refer to French-American-British classification subtypes (* indicates the expression of AURKA mRNA relative to the mean expression levels across 5 PBMC samples from healthy donors was determined by qRT-PCR and calculated using the comparative ΔCt method). Error bars represent SDs.

AURKA207-215–specific TCR-transduced CD8+ T cells kill freshly isolated leukemia cells in vitro. Freshly isolated HLA-A*0201+ (n = 3) or HLA-A*0201 (n = 3) acute or chronic myeloid leukemia cells overexpressing AURKA mRNA were used as targets in 51Cr-release assays with AURKA207-215–specific TCR-transduced CD8+ T cells at the indicated effector:target (E/T) ratios. AML, acute myeloid leukemia; BC, blast crisis; CML, chronic myeloid leukemia. M1, M2, and M4 refer to French-American-British classification subtypes (* indicates the expression of AURKA mRNA relative to the mean expression levels across 5 PBMC samples from healthy donors was determined by qRT-PCR and calculated using the comparative ΔCt method). Error bars represent SDs.

Close Modal

or Create an Account

Close Modal
Close Modal